



Discovery Fueled by Ultra-Sensitivity

Quanterix Corporation Announces Pricing of Initial Public Offering

December 7, 2017

LEXINGTON, Mass.--(BUSINESS WIRE)--Dec. 6, 2017-- [Quanterix Corporation](#), a company with a next generation, ultra-sensitive digital platform that advances precision health, today announced the pricing of its initial public offering of 4,275,200 shares of its common stock at a public offering price of \$15.00 per share for aggregate gross proceeds of \$64,128,000. In addition, Quanterix has granted the underwriters a 30-day option to purchase up to 641,280 additional shares of common stock at the initial public offering price, less the underwriting discount. The shares are scheduled to begin trading on The Nasdaq Global Market under the ticker symbol "QTRX" on December 7, 2017, and the offering is expected to close on December 11, 2017, subject to customary closing conditions.

J.P. Morgan Securities LLC, Leerink Partners LLC and Cowen and Company, LLC are serving as joint book-running managers for the offering. BTIG, LLC and Evercore Group L.L.C. are serving as co-managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on December 6, 2017. The offering will be made only by means of a prospectus. A copy of the final prospectus related to the offering will be filed with the Securities and Exchange Commission and may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (866) 803-9204; Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132 or by email at syndicate@leerink.com; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or by calling (631) 274-2806 or by faxing (631) 254-7140.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains certain forward-looking statements, including statements with regard to Quanterix Corporation's proposed initial public offering. Words such as "expects," "anticipates" and "intends" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the initial public offering discussed above will be completed on the terms described. Completion of the proposed initial public offering and the terms thereof are subject to numerous factors, many of which are beyond the control of the Company, including, without limitation, failure of customary closing conditions and the risk factors and other matters set forth in the prospectus included in the registration statement, in the form last filed with the Commission. Quanterix undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

About Quanterix

Quanterix is a company digitizing biomarker analysis with the goal of advancing the science of precision health. The company's digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix' technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20171206006455/en/>

Source: Quanterix Corporation

Quanterix PR Contact:

PAN Communications
Lauren Kaufman, 617-502-4300
quanterix@pancomm.com
or

Quanterix IR Contact:

Joe Driscoll, 617-301-9400
Chief Financial Officer
jdriscoll@quanterix.com